Format

Send to

Choose Destination
Expert Rev Vaccines. 2009 Jun;8(6):791-808. doi: 10.1586/erv.09.27.

Current status of toxoplasmosis vaccine development.

Author information

1
Gdańsk University of Technology, Chemical Faculty, Department of Microbiology, Narutowicza 11/12, 80-952 Gdańsk, Poland. kur@pg.gda.pl

Abstract

Toxoplasmosis, caused by an intracellular protozoan parasite, Toxoplasma gondii, is widespread throughout the world. The disease is of major medical and veterinary importance, being a cause of congenital disease and abortion in humans and domestic animals. In addition, recently it has gained importance owing to toxoplasma encephalitis in AIDS patients. In the last few years, there has been considerable progress towards the development of a vaccine for toxoplasmosis, and a vaccine based on the live-attenuated S48 strain was developed for veterinary uses. However, this vaccine is expensive, causes side effects and has a short shelf life. Furthermore, this vaccine may revert to a pathogenic strain and, therefore, is not suitable for human use. Various experimental studies have shown that it may be possible to develop a vaccine against human toxoplasmosis. Recent progress in knowledge of the protective immune response generated by T. gondii and the current status of development of a vaccine for toxoplasmosis are highlighted.

PMID:
19485758
DOI:
10.1586/erv.09.27
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center